The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
Official Title: A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Study ID: NCT02771626
Brief Summary: This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Honor Health, Scottsdale, Arizona, United States
Stanford University, Palo Alto, California, United States
University of Colorado, Aurora, Colorado, United States
University Cancer Blood Center, Athens, Georgia, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Karmanos Caner Center, Detroit, Michigan, United States
New York University, New York, New York, United States
Columbia University Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University Hospitals Cleveland, Cleveland, Ohio, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Vanderbilt University, Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Seattle Cancer Care Alliance/University of Washington, Seattle, Washington, United States
Northwest Medical Specialties, Tacoma, Washington, United States
Name: Sam Whiting, MD, PhD
Affiliation: Calithera Biosciences, Inc
Role: STUDY_DIRECTOR